Stockreport

Viridian Therapeutics Full Year 2023 Earnings: Misses Expectations [Yahoo! Finance]

Viridian Therapeutics, Inc.  (VRDN) 
PDF US$5.31 loss per share (further deteriorated from US$4.05 loss in FY 2022). All figures shown in the chart above are for the trailing 12 month (TTM) period Viridian [Read more]